La vendita allo scoperto per Prestige Consumer dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Prestige Consumer. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Prestige Consumer (NYSE:PBH) Azioni, Report sulle vendite allo scoperto

Prestige Consumer

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer Healthcare Inc

Pathfinder Bancorp Inc

PARAMOUNT BED CO ORD by Paramount Bed Co., Ltd.

Paramount Bed Holdings Co Ltd

PBS Holding Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

Paliburg Holdings Ltd

Jefferies analyst Stephanie Wissink assumes Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Hold rating and raises Price Target to $76.

News

Price Target

Initiation

Analyst Ratings

Jefferies Assumes Prestige Consumer at Hold, Raises Price Target to $76

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $93 to $95.

DA Davidson Maintains Buy on Prestige Consumer, Raises Price Target to $95

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and maintains $93 price target.

DA Davidson Maintains Buy on Prestige Consumer, Maintains $93 Price Target

Guidance

Prestige Consumer Healthcare Reaffirms FY25 Outlook For Sales Of $1.125B - $1.14B (Est $1.129B), Adjusted EPS Of $4.40 - $4.46 (Est $4.40)

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.86 by 4.65 percent. This is a 15.09 percent decrease over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $267.142 million which beat the analyst consensus estimate of $260.414 million by 2.58 percent. This is a 4.36 percent decrease over sales of $279.309 million the same period last year.

Earnings

Earnings Beats

Prestige Consumer Q1 2025 Adj. EPS $0.90 Beats $0.86 Estimate, Sales $267.142M Beat $260.414M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Oppenheimer analyst Brian Nagel upgraded the rating for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Perform to Outperform, while raising the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57 on Thursday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley analyst Carlos De Alba upgraded Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) from Equal-Weight to Overweight and boosted the price target from $36.5 to $50. Alcoa shares gained 4% to close at $38.98 on Thursday. <a href="https://www.benzinga.com/quote/AA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Shagun Singh upgraded the rating for Outset Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) from Sector Perform to Outperform, while increasing the price target from $5 to $6. Outset Medical shares fell 1.5% to settle at $3.5850 on Thursday. <a href="https://www.benzinga.com/quote/OM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Carlos De Alba upgraded Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Equal-Weight to Overweight and boosted the price target from $49.5 to $62. Freeport-McMoRan shares gained 3.5% to close at $49.36 on Thursday. <a href="https://www.benzinga.com/quote/FCX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson analyst Linda Bolton Weiser upgraded the rating for Prestige Consumer Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) from Neutral to Buy, while raising the price target from $65 to $93. Prestige Consumer shares settled at $65.28 on Thursday. <a href="https://www.benzinga.com/quote/BVN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39431308/nvidia-applied-materials-and-2-other-stocks-insiders-are-selling">Nvidia, Applied Materials And 2 Other Stocks Insiders Are Selling</a>

Upgrades

Markets

Trading Ideas

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

DA Davidson analyst Linda Bolton Weiser upgrades Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) from Neutral to Buy and raises the price target from $65 to $93.

DA Davidson Upgrades Prestige Consumer to Buy, Raises Price Target to $93

Canaccord Genuity analyst Susan Anderson maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and maintains $80 price target.

Canaccord Genuity Maintains Buy on Prestige Consumer, Maintains $80 Price Target

Prestige Consumer Healthcare Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbh#NYSE">PBH</a>) delivered fourth-quarter fiscal 2024 earnings per share of $1.02, a 4.7% decline from the year-ago period&#39;s figure. The metric also missed the Zacks Consensus Estimate by 10.5%.
GAAP EPS for the quarter was 98 cents, a significant improvement from the year-ago loss of $4.78 per share.
For the full year, adjusted EPS was $4.21, flat year over year.
<h3>Revenues</h3>
Total revenues in the fiscal fourth quarter declined 3.1% year over year (down 2.9% on an organic basis) to $276.9 million and lagged the Zacks Consensus Estimate by 3.5%.
The disappointing revenue performance for the quarter was caused by supply chain pressure late in the fourth quarter that affected Prestige Consumer&#39;s ability to fulfill retailer orders.
Full-year revenues were $1.13 billion, unchanged from the fiscal 2023 level.
<h3>Segments in Detail</h3>
The company conducts its operations through two reportable segments &mdash; North American OTC Healthcare and International OTC Healthcare.
Revenues in the North American OTC Healthcare segment totaled $231.1 million, down 4.6% from the year-earlier quarter. Our model projected the segment&#39;s revenues to be $242.6 million in the fourth quarter.
The revenue performance for the quarter was due to the inability to supply customer orders late in the quarter in certain brands as well as a lower Women&#39;s Health category and the strategic exit of private label business.
Revenues in the International OTC Healthcare segment were $45.9 million, up 5.3% from the year-ago quarter&#39;s figure. The company reported strong performance across numerous brands and geographies. However, this was marred by poor supply chain constraints.
Our model projected revenues from this segment to be $44.4 million.
<div class="chart_embed">
<h3>Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise</h3>
<a href="https://www.zacks.com/stock/chart/PBH/price-consensus-eps-surprise-chart?icid=chart-PBH-price-consensus-eps-surprise-chart"><img alt="Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/65/1715868484.png" style="height:265px; width:577px" title="" /> </a>
Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote
</div>
<h3>Margins</h3>
The gross profit in the fiscal fourth quarter declined 1.1% year over year to $153.9 million.&nbsp; Meanwhile, the gross margin expanded 115 basis points (bps) year over year to 55.6% on a 5.6% increase in the cost of sales (excluding depreciation).
During the quarter, advertising and marketing expenses rose 21.5% to $37.5 million, while general and administrative expenses decreased 4.3% to $26.5 million. Adjusted operating income in the quarter under review was $89.9 million, highlighting a decrease of 7.3%. The adjusted operating margin contracted 147 bps to 32.5%.
<h3>Financial Update</h3>
Prestige Consumer exited the fiscal fourth quarter with cash and cash equivalents of $46.5 million compared with the $63.6 million recorded at the end of the fiscal third quarter. Long-term debt totaled $1.13 billion, down from $1.20 billion at the end of fiscal third quarter.
The cumulative net cash provided by operating activities at fourth-quarter end was $248.9 million compared with $229.7 million in the year-ago period. The cumulative adjusted free cash flow at the end of the fiscal fourth quarter was $239.4 million compared with $221.9 million in the year-ago period.
<h3>Guidance</h3>
The company provided its initial fiscal 2025 organic revenue growth and EPS outlook.
Revenues for the full year are anticipated in the range of $1.125 billion-$1.140 billion. Organic revenue growth for the full year is anticipated to be approximately 1%. The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $1.16 billion.
Prestige Consumer expects fiscal 2025 EPS to be in the range of $4.40-$4.46. The Zacks Consensus Estimate for fiscal 2025 EPS stands at $4.61.
Free cash flow for the full year is likely to be $240 million or more.
<h3>Our Take</h3>
PBH exited the fiscal fourth quarter of 2024 with lower-than-expected revenues and earnings. &nbsp;The company noted that strong consumption trends and organic international segment growth were more than offset by supply chain pressure as well as continued Women&#39;s Health category weakness and the strategic exit of the private label business.Within the North American OTC segment, headwinds related to the strategic exit of the private-label business and weakness in certain non-core brands marred the strength of the Eye and Ear Care category.
The contraction of the adjusted operating margin during the quarter is discouraging.
<h3>Zacks Rank and Key Picks</h3>
Prestige Consumer currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Medpace (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>), ResMed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) and Encompass Health Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ehc#NYSE">EHC</a>).
Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 EPS of $3.20, which beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million improved 17.7% from last year&#39;s comparable figure.
Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry&#39;s 12.3%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.
ResMed, carrying a Zacks Rank #2 (Buy), reported first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.
RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry&#39;s 15.7%. The company delivered a four-quarter average earnings surprise of 2.8%.
Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.
EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry&#39;s 11.7% growth. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%.
<a href="https://www.zacks.com/stock/news/2274934/prestige-consumer-pbh-q4-earnings-miss-operating-margin-falls?cid=CS-BENZ-FT-analyst_blog|earnings_article-2274934">To read this article on Zacks.com click here.</a>

Earnings Misses

MEDP

Prestige Consumer Q4 Earnings Miss, Operating Margin Falls

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Neutral and maintains $65 price target.

DA Davidson Maintains Neutral on Prestige Consumer, Maintains $65 Price Target

WIIM

Prestige Consumer shares are trading lower after the company reported worse-than-expected Q4 financial results and issued weak guidance.

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) to report quarterly earnings at 82 cents per share on revenue of $12.53 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Cisco shares rose 0.1% to $49.00 in after-hours trading.</li>
<li>Prestige Consumer Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported worse-than-expected financial results for the fourth quarter and issued weak guidance. Prestige Consumer Healthcare shares dipped 7.7% to $66.00 in the after-hours trading session.</li>
<li>Analysts are expecting Arcos Dorados Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) to post quarterly earnings at 17 cents per share on revenue of $1.02 billion. The company will release earnings before the markets open. Arcos Dorados shares rose 1.7% to $11.40 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
<ul>
<li>Infinera Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) reported weak preliminary financial results for the first quarter. The company said it sees preliminary adjusted loss of 17 cents per share, versus market expectations for a loss of 13 cents per share. It expects preliminary revenue of $306.9 million for the quarter, down from estimates of $336.995 million. Infinera shares tumbled 10.8% to $5.17 in the after-hours trading session.</li>
<li>Analysts expect Dole plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOLE#NYSE">DOLE</a>) to post quarterly earnings at 31 cents per share on revenue of $2.12 billion before the opening bell. Dole shares rose 1.2% to $12.41 in after-hours trading.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38817342/jim-cramer-says-nu-skin-is-overvalued-praises-fabulous-pure-storage">Jim Cramer Says Nu Skin Is &#8216;Overvalued,&#8217; Praises &#8216;Fabulous&#8217; Pure Storage</a>

Pre-Market Outlook

ARCO

CSCO

DOLE

INFN

Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday

Buybacks

Prestige Consumer Healthcare On May 6 Authorized Repurchase Of Up To $300M

Prestige Consumer Healthcare Sees FY25 Revenue Growth ~1%, EPS $4.40-$4.46 vs $4.62 Est.

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $1.02 per share which missed the analyst consensus estimate of $1.14 by 10.53 percent. The company reported quarterly sales of $277.00 million which missed the analyst consensus estimate of $287.47 million by 3.64 percent. This is a 3.10 percent decrease over sales of $285.87 million the same period last year.

Prestige Consumer Q4 2024 Adj EPS $1.02 Misses $1.14 Estimate, Sales $277.00M Miss $287.47M Estimate

<h3>Gainers</h3>
<ul>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKLI

ARQT

BBLG

BCAB

BOLT

IRIX

OCEA

OPRX

SINT

VVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Companies Reporting Before The Bell</h3>
&bull; EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million.
&bull; NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $182.13 million.
&bull; Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $1.61 billion.
&bull; Hibbett (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) is projected to report quarterly earnings at $2.55 per share on revenue of $477.49 million.
&bull; RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $66.52 million.
&bull; KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.32 million.
&bull; Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is estimated to report earnings for its fourth quarter.
&bull; Desktop Metal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DM#NYSE">DM</a>) is projected to report quarterly loss at $0.05 per share on revenue of $50.83 million.
&bull; Paltalk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALT#NASDAQ">PALT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $3.53 million.
&bull; GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) is likely to report quarterly earnings at $0.58 per share on revenue of $224.15 million.
&bull; Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is estimated to report quarterly earnings at $1.66 per share on revenue of $6.89 billion.
&bull; Buckle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) is expected to report quarterly earnings at $1.44 per share on revenue of $383.63 million.
&bull; Summit Midstream Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMLP#NYSE">SMLP</a>) is projected to report earnings for its fourth quarter.
&bull; CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $58.86 million.
&bull; ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is likely to report quarterly loss at $0.26 per share on revenue of $10.69 million.
&bull; Tredegar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>) is estimated to report earnings for its fourth quarter.
&bull; Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) is expected to report quarterly loss at $0.07 per share on revenue of $304.52 million.
&bull; Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is likely to report quarterly loss at $0.12 per share on revenue of $32.06 million.
&bull; Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) is likely to report quarterly earnings at $0.11 per share on revenue of $136.70 million.
&bull; Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $111.85 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Consumer Pf Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSS#NASDAQ">CPSS</a>) is estimated to report earnings for its fourth quarter.
&bull; Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is projected to report quarterly earnings at $0.71 per share on revenue of $60.65 million.
&bull; High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $94.67 million.
&bull; Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $32.65 million.
&bull; Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) is likely to report quarterly loss at $1.19 per share on revenue of $11.52 million.
&bull; AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $66.80 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALTI

BFRI

CBAT

CPSS

GRPN

HIBB

HITI

KVHI

LEGH

OXSQ

PALT

PRPH

SHCO

SMLP

Earnings Scheduled For March 15, 2024

CORRECTION: Prestige Consumer Healthcare Raised 2024 Diluted EPS Guidance To Approximately $4.33 From Prior Guidance Of $4.27-$4.32 Versus Consensus Of $4.32

Prestige Consumer Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results and raised fiscal 2024 diluted EPS guidance.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Palatin Technologies (PTN – Research Report) and Prestige Consume...

Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Prestige Consumer Healthcare (PBH)

Susan Anderson, an analyst from Canaccord Genuity, maintained the Buy rating on Prestige Consumer Healthcare (PBH – Research Report). The associate...

Prestige Consumer Healthcare: A Strong Buy Amid Solid Financials and Strategic Growth Initiatives

Tracking John Rogers' Ariel Investments Portfolio - Q1 2024 Update

Ariel Investments Small Cap Value Concentrated Q2 2024 Commentary

Prestige Consumer Healthcare Q1 2025 Earnings Preview

Prestige Consumer Healthcare beats top-line and bottom-line estimates; reaffirms FY24 outlook

Prestige Consumer Healthcare Inc. 2025 Q1 - Results - Earnings Call Presentation

Prestige Consumer Healthcare Inc. (PBH) Q2 2024 Earnings Call Transcript

Tracking John Rogers' Ariel Investments Portfolio - Q2 2024 Update

Analyst Susan Anderson from Canaccord Genuity maintained a Buy rating on Prestige Consumer Healthcare (PBH – Research Report) and keeping the price...

Prestige Consumer Healthcare: A Strong Buy on Brand Resilience and Strategic Growth Opportunities

APTV

ATGE

BAIDF

BIDU

BOKF

CHKP

GILD

GNRC

GNTX

LESL

MGRB

MGRD

MGRE

MSFT

MSGE

NTRS

NTRSO

NVST

OSWWF

PARA

PARAA

REZI

SAEF

SPHR

SRCL

ZBRA

Press Releases

General

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results

Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results

Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results

Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2025 Results

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Earnings Results

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Prestige Consumer

Vendite allo scoperto

Prestige Consumer (NYSE:PBH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO